Business Wire

Clear Sailing Forecast for Europe’s Business Travel Market


Western Europe’s business travel spending is projected to increase to $211.2 billion USD in 2016 and top out at $225.6 billion USD in 2017, 6.3% and 6.8% growth respectively. Those figures are among the key findings in the most recent GBTA BTI™ Outlook – Western Europe report, conducted by the GBTA Foundation, the education and research arm of the Global Business Travel Association (GBTA), and sponsored by Visa, Inc.

The GBTA BTI™ Outlook – Western Europe report looks at the five largest business travel markets in Europe: Germany, the United Kingdom, France, Italy and Spain that together make up 70 percent of Western Europe’s business travel market, and serve as a strong indicator for the European business travel market more broadly. Taken together, the business travel trends of these five countries demonstrate that Western Europe’s business travel confidence and demand is growing due to a number of positive factors that are projected to continue into next year.

“What’s most impressive about these results is that Europe has faced a seemingly endless array of challenges recently,” said Catherine McGavock, GBTA’s Regional Vice President – EMEA. “From the Greek debt crisis to the influx of Syrian refugees, terrorist attacks in several European capitals, and the pending U.K. referendum on possibly exiting the bloc, the business travel market has not only endured, but thrived – growing at a greater rate over the last year than many of the other large business travel markets across the globe.”

Business Travel Growth Seen in Northern and Southern Europe

Europe’s positive business travel growth will continue at a respectable rate, and that growth is not confined to the continent’s larger, northern economies. Europe’s southern tier is also faring better than expected with an improved outlook as consumer confidence returns and a favorable business climate promulgated by low interest rates and oil prices and rising demand and investment continue. Italy and Spain, for example, will see growth rates of 7.3 percent and 11.9 percent, respectively from 2015 to 2017.

A “Brexit” Effect?

On 23 June, U.K. voters will vote on whether or not to exit the European Union. Most polls show that the referendum will not pass and the U.K. will stay in the European Union. Even if voters in the U.K. do decide to vote for “Brexit,” given the overall size of the EU economy relative to U.K., it is likely that the fallout should be manageable for both sides. There are specific European countries that are very closely aligned with the U.K. economy, however, where the impact would be more significant, such as Ireland.

For individual business travelers, perhaps the biggest effect the Brexit would have is on the ease in which they could travel to and from the United Kingdom. As a European Union member, travel is currently unrestricted within the bloc making business travel across borders much easier than it had been previously. Perhaps the greatest risk of Brexit is the inspiration it may provide to other countries to test membership, calling into question the existence of the Union. The financial, economic and cultural upheaval from that extreme shift could be significant.

Despite the looming Brexit referendum, refugee crisis and continuing global economic uncertainty, Western Europe’s business travel market is robust – and serves as a harbinger of positive growth and more consumer and business confidence in the coming months and years ahead.

Country-Level Business Travel Outlooks

Germany – a $63.5 billion USD market – is leading the way, with business travel growth of 7.6 percent projected in 2016 and 9.3 percent growth in 2017. Spending on domestic business travel is increasing by 7.1 percent this year and projected to increase by 9.3 percent next year. International outbound business travel will grow 9.8 percent in 2016 and 9.5 percent in 2017. Domestic business travel accounts for 80 percent of all business travel in Germany.

The United Kingdom – a $47.1 billion USD market – is expected to grow at 7.9 percent in 2016 and 6.9 percent in 2017. Spending on domestic business travel will grow at 6.9 percent in 2016 and 5.8 percent in 2017, while international outbound travel will grow at 9.8 percent in 2016 and 8.9 percent in 2017. Domestic business travel accounts for 65 percent of all business travel in the United Kingdom.

France – a $37.1 billion USD market – is expected grow at 3.9 percent in 2016 and 5.8 percent in 2017. Spending on domestic business travel will grow at 3.0 percent this year and 5.7 percent next year, while international outbound travel will grow at 5.6 percent in 2016 and 6.1 percent in 2017. Domestic business travel accounts for 65 percent of all business travel in France.

Spain – a $19.4 billion USD market – is expected to grow at 6.5 percent in 2016 and 5.1 percent in 2017. Spending on domestic business travel will grow at 7.0 percent in 2016 and 4.3 percent in 2017, while international outbound travel will grow at 4.7 percent in 2016 and 7.9 percent in 2017. Domestic business travel accounts for almost 80 percent of all business travel in Spain.

Italy – a $31.6 billion USD market – is expected to grow at 3.6 percent in 2016 and 3.5 percent in 2017. Spending on domestic business travel will grow at 3.0 percent this year and 3.4 percent next year. International outbound travel will grow at 8.4 percent in 2016 and 4.4 percent in 2017. Domestic business travel accounts for almost 90 percent of all business travel in Italy.

The GBTA BTI™ Outlook – Western Europe 2016 H1 report is available exclusively to GBTA members by clicking here and non-members may purchase the report through the GBTA Foundation by emailing To view a preview of this research, please click here.

About the GBTA Foundation

The GBTA Foundation is the education and research foundation of the Global Business Travel Association (GBTA), the world’s premier business travel and meetings trade organization headquartered in the Washington, D.C. area with operations on six continents. Collectively, GBTA’s 7,000-plus members manage more than $345 billion of global business travel and meetings expenditures annually. GBTA provides its growing network of more than 28,000 travel professionals and 125,000 active contacts with world-class education, events, research, advocacy and media. The Foundation was established in 1997 to support GBTA’s members and the industry as a whole. As the leading education and research foundation in the business travel industry, the GBTA Foundation seeks to fund initiatives to advance the business travel profession. The GBTA Foundation is a 501(c)(3) nonprofit organization. For more information, see and

Contact information

Global Business Travel Association
Colleen Lerro Gallagher, +1 703-236-1133

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Emmaus Life Sciences Announces the New England Journal of Medicine has Published the Phase 3 Trial Results of Endari™ (L-Glutamine Oral Powder) in Sickle Cell Disease18.7.2018 21:45Pressemelding

VIEW E-MEDIA KIT – Emmaus Life Sciences, Inc. (Emmaus) announced today that the New England Journal of Medicine (NEJM) has published the results of its 48-week phase 3 clinical trial of Endari™ (L-glutamine oral powder) which supported the FDA approval in July 2017 to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. The article reports results that showed significantly fewer sickle cell crises in those receiving Endari compared to placebo by 25 percent; p=0.005 (median 3 vs. median 4) and significantly fewer hospitalizations by 33 percent; p=0.005 (median 2 vs. median 3). Additional findings showed lower cumulative days in hospital of 41 percent; p=0.02 (median 6.5 days vs. median 11 days) and a lower incidence of acute chest syndrome (ACS) by more than 60 percent; p=0.003 (13 of 152 patients [8.6%] had at least 1 ACS compared with 18 of 78 in the placebo group [23.1%]). The most common adverse reactions, occurring in great

Tigo Releases State-of-the-art Wireless Technology – Mesh – as the New Solar Communication Architecture for the TS4 Platform18.7.2018 19:41Pressemelding

Tigo®, pioneer of the smart modular Flex MLPE platform, today announced the release of its new Mesh communication architecture. This state-of-the-art wireless technology directly translates to customer benefits – including simplifying the solar design process and accelerating the commissioning steps. The complete Tigo solution uses a simple yet powerful data collection technology that covers the widest ranges of residential & commercial installations at the lowest cost. With Mesh and the recently announced Tigo Access Point (TAP), customers eliminate the need to address any roof obstruction or orientation constraint. To learn more about Mesh and TAP, register for Tigo’s free, online webinar “The Future of Solar is Wireless” on Wednesday July 25th, 2018 at 10am PDT. This press release features multimedia. View the full release here: Mesh is Tigo's proprietary software that allows each TS4 unit to act as a repeater, extending the

ViiV Healthcare Shares Data from Landmark 2-Drug Regimen Trials At AIDS 201818.7.2018 17:21Pressemelding

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting over 20 abstracts, including data from the landmark GEMINI 1 & 2 clinical trials, at the 22nd International AIDS Conference (AIDS 2018), 23-27 July 2018, in Amsterdam, The Netherlands. The data being presented this year has a strong focus on novel exploratory therapeutic options and innovative treatment strategies, as well as improving awareness and understanding of key issues that continue to affect the HIV community. John C Pottage, Jr, MD, Chief Scientific and Medical Officer, ViiV Healthcare, commented, “As we see advancements in the treatment options available to people living with HIV, our research efforts over the past few years have been focused on moving beyond viral load and addressing some of the unresolved issues that people living with HIV face, such as the potential long-term risks and toxicities that can be associated with li

Xilam: H1 2018 Revenue: +50%18.7.2018 16:00Pressemelding

Regulatory News: The Xilam Group (Paris:XIL) posted consolidated H1 2018 revenue of EUR 13,866 thousand, an increase of 50%. This increase represents an excellent performance, as it follows on the heels of growth of 54% in H1 2017. Revenue for the first part of this financial year breaks down as follows. In thousands of euros 30.06.2018 (1) 30.06.2017 Change New productions 8,465 4,571 +85% Catalogue 5,385 4,652 +16% Other 16 16 +0% Revenue and subsidies 13,866 9,239 +50% (1) Unaudited data. Remarkable success for new releases +85% Excellent H1 growth was driven by the two main businesses, New Productions and Catalogue. In New Productions, H1 deliveries generated record revenue of EUR 8,465 thousand, an 85% increase compared with H1 2017, and confirmed Xilam’s position as a major European animation company. Catalogue revenue was up 16% compared with H1 2017, thanks again to traditional TV channels and digital platforms, in both France and abroad. A fast-paced delivery schedule Thanks t

Department for International Trade: Life Sciences at the Heart of UK Economy18.7.2018 12:38Pressemelding

The Government will today (Wednesday 18 July) host the second in a series of roundtables with stakeholders from key life science businesses, demonstrating the importance of the sector to the UK economy. The Chancellor, International Trade Secretary, Business Secretary and Health and Social Care Secretary will be amongst those that meet with senior representatives from leading UK and international life sciences companies as the UK positions itself as the global home of health innovation, welcoming overseas investment and seeking to boost exports in the process. Discussions at the roundtable will focus on how the future of the Life Sciences sector will be supported by the delivery of our modern Industrial Strategy, ensuring that the UK is ‘open for business’ with a positive business environment, our ambitions for a comprehensive agreement with the EU on our future relationship and the development and implementation of our independent trade policy. To date, the government has engaged sign

Universal Laser Systems Expands Its Materials Database with 3M, Victrex and Dexmet Materials18.7.2018 12:05Pressemelding

Universal Laser Systems (ULS) announces the addition of 3M™, Victrex® and Dexmet materials to its materials database, the most extensive repository of laser material processing parameters for materials in the range of 10 watts to 500 watts. The 3M, Victrex and Dexmet materials new to the ULS materials database were specifically added for laser processing with the ULTRA and XLS platforms, suited for high accuracy and precision laser cutting, laser ablation and laser surface modification. The materials include: 3M™ Extreme Sealing Tape 4412N 3M™ Thermally Conductive Silicone Interface Pad 5516 Victrex® APTIV® PEEK Film Dexmet PolyGrid® 8PTFE10-125ST Expanded PTFE Dexmet MicroGrid® AL 25 Expanded Aluminum Laser processing notes, describing the results of the laser-material interaction for these materials, are also available in the Materials Library on the ULS website to help potential customers explore the advantages of deploying laser technology within their manufacturing, research and d